60
Participants
Start Date
June 21, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
MIT-001 plus CCRT
MIT-001 IV-infusion plus CCRT
Seoul National University Bundang Hospital, Gyeonggi-do
James P. Wilmot Cancer Center, Rochester
The Catholic University of Korea Saint Vincent's Hospital, Suwon
Wake Forest Baptist Health - Comprehensive Cancer Center, Winston-Salem
James Cancer Hospital Solove Research Institute, Columbus
Jeonbuk National University Hospital, Jeonju
Cancer Center of Kansas, Wichita
Banner MD Anderson Cancer Center, Gilbert
Norris Comprehensive Cancer Center, Los Angeles
Keimyung University Dongsan Hospital, Daegu
Chungnam National University Hospital, Daejeon
National Cancer Center, Goyang-si
Inha University Hospital, Incheon
Hanyang University Seoul Hospital, Seoul
Seoul National University Hospital, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
MitoImmune Therapeutics
INDUSTRY